Macrogenics (MGNX) Cash from Financing Activities (2012 - 2026)
Macrogenics (MGNX) posted quarterly Cash from Financing Activities of -$207000.0 for Q1 2026, up 26.6% year-over-year from -$163512.6 in Q1 2025, and down 463.16% quarter-over-quarter from $57000.0 in Q4 2025.
Macrogenics (MGNX) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Cash from Financing Activities for 15 consecutive years, with -$207000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 26.6% year-over-year to -$207000.0; the TTM figure through Mar 2026 stood at $69.6 million (up 16083.49% YoY), while the FY2025 annual figure was $69.5 million, up 7141.04% from the prior year.
- Cash from Financing Activities fell to -$207000.0 in Q1 2026 per MGNX's latest filing, from $57000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $100.1 million in Q1 2023 and bottomed at -$282000.0 in Q1 2025.
- Historically, Cash from Financing Activities has averaged $14.8 million across 5 years, with a median of $248000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 270489.19% — and 2025, when it tumbled 213.71%.
- Macrogenics' Cash from Financing Activities stood at $1.4 million in 2022, then plunged by 79.91% to $273000.0 in 2023, then sank by 43.22% to $155000.0 in 2024, then tumbled by 63.23% to $57000.0 in 2025, then tumbled by 463.16% to -$207000.0 in 2026.
- Business Quant data shows MGNX's Cash from Financing Activities at -$207000.0 in Q1 2026, $57000.0 in Q4 2025, and $69.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -207,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -207,000.00 |
| Mar 31, 2026 | -207,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Jun 30, 2025 | 69.74 Mn |
| Jun 30, 2025 | 69.74 Mn |
| Mar 31, 2025 | -282,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Sep 30, 2023 | 49.91 Mn |
| Sep 30, 2023 | 49.91 Mn |